The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the Tumor, Node, Metastasis Classification for Lung Cancer

Frances A. Shepherd, MD, FRCPC,* John Crowley, PhD,† Paul Van Houtte, MD,‡ Pieter E. Postmus, MD, PhD,¶ Desmond Carney, MD, PhD,‖ Kari Chansky, MS,† Zeba Shaikh, BSc,** and Peter Goldstraw, FRCS, on behalf of the International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions

Background: Small cell lung cancer (SCLC) is usually classified using the limited and extensive definition. The tumor, node, metastasis (TNM) classification should also be applicable to SCLC, but it has only been reported in small surgical series. The current analysis looks to the impact of the TNM system on the clinical staging of SCLC and of the new International Association for the study of Lung Cancer (IASLC) proposals.

Methods: Using the IASLC database, survival analyses were performed for clinically staged patients. Prognostic groups were compared, and the new IASLC TNM proposals were applied to this population and to the Surveillance, Epidemiology, and End Results (SEER) database.

Results: The IASLC database contained 12,620 eligible cases of small cell histology. TNM staging was available for 8088 patients. Survival was directly correlated to both T and N category. Differences were more pronounced in patients without mediastinal or supraclavicular nodal involvement. Stage grouping using the sixth edition of TNM also differentiates survival except between IA and IB. Patients with pleural effusion regardless of the cytology have an intermediate prognosis between limited and extensive disease. The IASLC proposals for the seventh edition of the TNM classification also apply to this series of SCLC and to the SEER database.

Conclusion: TNM staging is recommended for SCLC, and stratification by stage I-III should be incorporated in clinical trials of early-stage disease. Further studies are needed to clarify the impact of pleural effusion and the extent of N3 disease.

Key Words: Small cell lung cancer, Staging.

Lung cancer is the leading cause of cancer-related mortality in the western world, with recent statistics showing that it accounts for more than 1,000,000 deaths each year globally.1 Small cell lung cancer (SCLC) represents only 15% to 20% of lung cancers overall, with incidence rates declining among men but continuing to increase among women in most countries.2 It is distinguished by its rapid growth rate, early dissemination to regional lymph nodes and distant sites, and its sensitivity to chemotherapy and radiotherapy.3 The introduction of chemotherapy to the treatment of SCLC led to significant improvements in median and 5-year survival rates in the 1970s through 1990s,4 but recently survival seems to have reached a plateau for both localized and advanced SCLC.

Staging of lung cancer is second in importance only to the pathologic determination of cell type. Accurate staging provides prognostic information, and stage determines treatment strategies for all types of lung cancer. The first staging system for SCLC was introduced in the 1950s by the Veterans’ Administration Lung Study Group (VALSG) for use in...
their randomized clinical trials. This simple system divided SCLC into two disease subgroups termed “limited” and “extensive” disease. Limited disease (LD) was characterized by tumors confined to one hemithorax, although local extension and ipsilateral, supraclavicular nodes could also be present if they could be encompassed in the same radiation portal as the primary tumor. No extrathoracic metastases could be present. All other disease was classified as extensive disease (ED).

In 1989, the International Association for the Study of Lung Cancer (IASLC) issued a consensus report that, for the first time in 30 years, introduced changes to the VALSG staging system. This report suggested that LD should be expanded to include tumors limited to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal and ipsilateral and contralateral supraclavicular nodes. They also recommended that patients with ipsilateral pleural effusion, regardless of whether cytology is positive or negative, be considered to have LD if no extrathoracic metastases were detected.

The tumor, node, metastasis (TNM) staging systems of the American Joint Committee on Cancer Staging (AJCC) and the Union Internationale Contre le Cancer (UICC) are also applicable to SCLC, but they are used less frequently in clinical practice because these two staging systems have historically relied on surgical confirmation for their accuracy, and patients with SCLC seldom present at a stage for which surgery is appropriate. However, in small surgical series of patients with SCLC, the TNM staging system has been shown to be prognostic of outcome. TNM staging in non-surgical series is rarely reported.

The IASLC has established a database containing staging and a minimum of 5-year survival data for more than 100,000 patients with lung cancer from around the world, presenting between 1990 and the end of 2000. Among these are more than 12,000 patients with SCLC. This database was established to assess the current stage categories as defined by the AJCC and the UICC sixth edition, with the goal of redefining and regrouping of T and N descriptors, to make recommendations for change if and where appropriate. These analyses were performed initially on the large 67,725 case database, reserving 9133 cases for further validation. The random selection process was stratified by type of database submission and time of case entry (1990–1995 vs 1995–2000). Selection of a final stage grouping proposal from among the candidate schemes was based on its statistical properties in the training set and its relevance to clinical practice and was arrived at by consensus.

Analyses focusing on sixth edition TNM were applied to the subset of SCLC cases for which complete clinical TNM stage was provided. The newly proposed TNM stage groupings were applied to the set of SCLC cases that had sufficient descriptors to reclassify according to the new TNM stage scheme. Analyses focusing on pleural effusion required only a designation of limited or extensive stage disease by the VALSG system (or adequate TNM staging to derive this determination) and sufficient information to determine presence/absence of pleural effusion.

Survival was measured from the date of entry (date of diagnosis for registries and the date of registration for protocols) and was estimated by the Kaplan-Meier method. Prognostic groups were compared formally by Cox proportional hazards regression analysis, using the SAS System for Windows Version 9.0 PHREG procedure.

RESULTS
Population
Of the 100,869 patients with information submitted to the IASLC database, 81,015 met the initial screening requirements of having a new diagnosis rather than recurrent diagnosis of either SCLC or NSCLC, presentation from 1990 to the end of 2000, adequate follow-up for survival, and adequate staging information at baseline. From the 13,290 SCLC...
cases meeting the initial screen, 670 with mixed histology or with conflicts between TNM and extent of disease were excluded, to yield 12,620 eligible cases of small cell histology. Of the 12,620 eligible SCLC cases, 4532 had LD or ED classification only (Table 1). TNM staging was available for 8088 patients: 3430 cM0 cases had full clinical TNM data, 343 had full pathologic TNM staging, and 4530 were classified as cM1 (clinical metastatic disease). The 12,620 cases originated from four global regions: Europe (56%), North America (35%), Asia (3%), and Australia (6%). Of the cases, 52% were from clinical trials. 43% from population-based registries or single-institution series or registries, and the rest from consortia. For cases with complete clinical TNM staging, the proportions were: clinical trials 32%, population-based registries or single-institution series or registries 60%, and consortia 8% (Table 2). Because most patients with SCLC are staged only clinically, we focus on the clinical staging of this malignancy in this article; the surgical series will be reported separately. A complete listing of data contributors is given in Appendix A.

T Category

As shown in Figure 1A, increasing clinical T category, using the sixth edition TNM staging system was associated with progressively lower survival in patients who did not have evidence of metastatic (M1) involvement. Comparisons between T categories and 1- and 5-year survival rates are shown in Table 3. Patients with clinical T1 had significantly better survival than those with T categories 2–4. A comparison of clinical category T1 versus T2 yields a hazard ratio (HR) of 1.48 ($p < 0.0001$), and the trend continues with significant differences between T2 versus T3 and T3 versus T4 (see Table 3). The $p$ value for the ordered log rank test (a test against ordered alternatives for survival data) is less than 0.0001.28,29

N Category

As shown in Figure 1B and Table 4, increasing clinical N category was associated with progressively lower survival. Patients with clinical N0 or N1 tumors had significantly better survival than did those with N2 or N3 tumors. The difference between cN0 and cN1 is not significant (HR 1.02, $p = 0.76$). The cN2 and cN3, although significantly different, have similar median survivals (14 vs. 12 months, HR 1.18). The difference between the N1 and N2 is the largest (median 19 vs. 14 months, HR 1.40, $p = 0.0001$) and represents the primary separation for clinical N category. The $p$ value for the ordered log rank test is less than 0.0001.

Survival for clinical T categories within the four clinical N categories 0–3 is shown in Figure 2. Although increasing T category seems to be associated with worse survival in each N category, the differences seem to be clinically meaningful only for patients without mediastinal or supraclavicular nodal involvement.

Survival According to TNM Stage

Survival by clinical TNM stage sixth edition is shown in Figure 1C. The near superimposition of stage IA together with IIA, and stage IB with IIB, are most likely a reflection of the separation between the T1 cases (comprising IA and IIA) and the T2 and T3 (IB and IIB). Pair-wise comparisons between adjacent stage groupings are shown in Table 5. All differences are significant, but for the reason just discussed, the hazard ratio for IIA versus IB is the reverse of what would be expected.

Pleural Effusion

In the proposals from the IASLC for the forthcoming (seventh) edition of the TNM classification for lung cancer, the presence of a pleural effusion in patients with NSCLC will now be considered as M1 disease. In the SCLC database, information concerning the presence or absence of pleural effusion or other distant sites was available for 1258 patients with otherwise limited disease (1113 of whom were without pleural effusion, 145 with pleural effusion) and 4500 patients with ED with other metastatic sites. Of the 145 cases of LD with pleural effusion, 81 were actually designated as ED without any other metastatic sites. These 81 were assumed to have LD with pleural effusion. Surgically managed cases were excluded. As can be seen from Figure 3A, the survival of patients with LD with effusion is intermediate between those of patients with LD without effusion and patients with ED (ordered log rank $p$ value <0.0001).

The result of cytologic examination of the pleural effusion was available for only 68 patients in the database. As shown in Figure 3B, the survival of patients with LD with effusion, whether cytologically negative or positive, remained intermediate between those of patients with LD

---

TABLE 1. Summary of 12,620 Small Cell Lung Cancer Cases from the IASLC International Staging Project Database

<table>
<thead>
<tr>
<th>VALSG/IASLC Stage</th>
<th>Clinical TNM</th>
<th>Pathological TNM</th>
<th>Clinical and Pathological TNM</th>
<th>cM1</th>
<th>Extensive or Limited Only</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not classified</td>
<td>1819</td>
<td>127</td>
<td>193</td>
<td>1532</td>
<td>0</td>
<td>3671</td>
</tr>
<tr>
<td>Extensive</td>
<td>88</td>
<td>0</td>
<td>4</td>
<td>2998</td>
<td>2038</td>
<td>5128</td>
</tr>
<tr>
<td>Limited</td>
<td>1308</td>
<td>1</td>
<td>18</td>
<td>0</td>
<td>2494</td>
<td>3821</td>
</tr>
<tr>
<td>Total</td>
<td>3215</td>
<td>128</td>
<td>215</td>
<td>4530</td>
<td>4532</td>
<td>12620</td>
</tr>
</tbody>
</table>

VALSG, Veterans’ Administration Lung Study Group; IASLC, International Association for the Study of Lung Cancer; TNM, tumor, node, metastasis.
Proposals from the IASLC for Stage Groupings in the Seventh Edition of the TNM Classification for Lung Cancer

It was not possible to classify all SCLC cases according to the proposed IASLC stage groupings because details for the T descriptor frequently was inadequate, particularly with respect to size, presence of additional intrapulmonary nodules, and involvement of the pleura. Figure 4A shows survival according to the TNM stage sixth edition for the smaller cohort of patients \((n = 2464)\) with full T descriptor data. With the exception of the extremely small subgroup of eight patients with stage IIA, it can be seen that increasing stage is associated with progressively shorter survival. Figure 4B shows the survival of the same cohort of patients using the IASLC stage groupings proposed for the UICC seventh edition, and Figure 4C shows the proposed IASLC groupings applied to the much larger Surveillance, Epidemiology and End Results (SEER) data base of the National Cancer Institute. In the SEER database, for patients registered with an initial diagnosis of SCLC during the years 1998 through 2000 inclusive, the proposed IASLC system works well with increasing stage being associated with decreasing survival.

DISCUSSION

At the time of initial diagnosis, approximately two thirds of patients with SCLC have clinical evidence of hematogenous metastases \((M1)\); for the remaining one-third, most patients have clinical evidence of extensive nodal involvement in the hilar, mediastinal, and sometimes even the supraclavicular regions. For that reason, surgical resection is seldom offered; instead, patients are treated with systemic chemotherapy with or without radiation. Although TNM staging has been applied in small series of patients with SCLC treated either with surgery alone or with combined modality therapy including surgery, \(^9\)–\(^{21}\) a simpler staging system assigning patients to either LD or ED is used most frequently in clinical practice. \(^5\)–\(^6\) Patients with LD cancers (confined to the thorax) are treated with chemotherapy and thoracic radiation, whereas, for the most part, patients with ED (distant hematogenous metastases) receive only chemotherapy.

In general, it has been believed that more precise staging of SCLC using the TNM system does not provide extra guidance with respect to selection of treatment modality because so few patients are eligible for surgery. However, a more precise definition of nodal involvement may be of particular relevance for radiation treatment. The simple designation of LD does not provide adequate information for accurate radiotherapy planning because it does not differentiate between the presence or absence of ipsilateral and contralateral supraclavicular nodes, and ipsilateral and contralateral hilar or mediastinal nodes. According to the 1989 IASLC staging system for SCLC, all of these nodal stations are included in LD. In the modern era of conformal techniques and increasing radiation dose for SCLC, it is likely no longer appropriate to treat all patients with LD in the same way, and radiation fields must be determined using more precise nodal categories.

The SCLC subgroup of patients in the IASLC staging initiative represents the largest cohort of patients with this malignancy ever to be reported. In particular, it is the largest cohort of patients with SCLC to have been staged using the TNM system apart from small surgical series, most of which had fewer than 50 patients. \(^9\)–\(^{21}\) These surgical series clearly showed that TNM staging could identify patients with different prognoses.

The more important question, however, is whether the old VALSG and IASLC staging classifications should be abandoned and whether clinical TNM staging, as used for NSCLC, should be applied to SCLC as proposed by the UICC. In our large clinically staged series, patients with clinical T1 disease had significantly better survival than those with T2 disease \((HR 1.48, p < 0.0001)\) and all other T categories, although they represented only 13.7% of all patients. However, the test for trend among the four T groupings was highly significant. In a pattern of care study performed in Japan including only patients with limited disease, the T category was also a significant prognostic factor for survival in a multivariate analysis.\(^{18}\)

### TABLE 2. Sources of Small Cell Lung Cancer Cases with Complete TNM Stage

<table>
<thead>
<tr>
<th>Type of Database</th>
<th>Clinical TNM</th>
<th>Pathological TNM</th>
<th>Clinical and Pathological TNM</th>
<th>cM1</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registry</td>
<td>634</td>
<td>6</td>
<td>9</td>
<td>1720</td>
<td>2369</td>
</tr>
<tr>
<td>Surgical series</td>
<td>31</td>
<td>67</td>
<td>3</td>
<td>5</td>
<td>106</td>
</tr>
<tr>
<td>Clinical trial</td>
<td>1027</td>
<td>0</td>
<td>1</td>
<td>1556</td>
<td>2584</td>
</tr>
<tr>
<td>Series</td>
<td>742</td>
<td>2</td>
<td>31</td>
<td>596</td>
<td>1371</td>
</tr>
<tr>
<td>Consortium</td>
<td>240</td>
<td>11</td>
<td>171</td>
<td>263</td>
<td>685</td>
</tr>
<tr>
<td>Institutional registry</td>
<td>541</td>
<td>0</td>
<td>0</td>
<td>390</td>
<td>931</td>
</tr>
<tr>
<td>Surgical registry</td>
<td>0</td>
<td>42</td>
<td>0</td>
<td>0</td>
<td>42</td>
</tr>
<tr>
<td>Total</td>
<td>3215</td>
<td>128</td>
<td>215</td>
<td>4530</td>
<td>8088</td>
</tr>
</tbody>
</table>

TNM, tumor, node, metastasis.
With respect to N category, patients with clinical N0 or N1 tumors had significantly better survival than those with N2 or N3 tumors, although the difference between N0 and N1 was not significant, and the greatest difference in survival was seen between N1 and N2. It is likely that the patients with T1-2,N0-1,M0 tumors (i.e., stage IA, IB, IIA and IIB [N0 and N1]) are the same as those previously classified by the University of Toronto Lung Group as “very limited.”

Unfortunately, the database did not contain enough information to determine whether the survival of patients

**FIGURE 1.** Survival by (A) clinical T Category, (B) clinical N Category, and (C) clinical TNM category (sixth edition of TNM).
TABLE 3. Overall Survival Comparisons for Clinical Category T1 to T4 (any N) M0 Small Cell Lung Cancer, IASLC Data

<table>
<thead>
<tr>
<th>T Category</th>
<th>n</th>
<th>1-yr Survival (%)</th>
<th>5-yr Survival (%)</th>
<th>Comparison</th>
<th>HR</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>470</td>
<td>73</td>
<td>29</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>1396</td>
<td>62</td>
<td>15</td>
<td>T2 vs. T1</td>
<td>1.48</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>T3</td>
<td>564</td>
<td>55</td>
<td>11</td>
<td>T3 vs. T2</td>
<td>1.14</td>
<td>0.0185</td>
</tr>
<tr>
<td>T4</td>
<td>1000</td>
<td>49</td>
<td>10</td>
<td>T4 vs. T3</td>
<td>1.17</td>
<td>0.0055</td>
</tr>
</tbody>
</table>

HR, hazard ratio.

TABLE 4. Overall Survival Comparisons for Clinical Category N0–N3 (any T) M0 Small Cell Lung Cancer, IASLC Database

<table>
<thead>
<tr>
<th>N Category</th>
<th>n</th>
<th>1-yr Survival (%)</th>
<th>5-yr Survival (%)</th>
<th>Comparison</th>
<th>HR</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N0</td>
<td>750</td>
<td>68</td>
<td>24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>348</td>
<td>68</td>
<td>20</td>
<td>N1 vs. N0</td>
<td>1.02</td>
<td>0.7552</td>
</tr>
<tr>
<td>N2</td>
<td>1592</td>
<td>56</td>
<td>12</td>
<td>N2 vs. N1</td>
<td>1.40</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>N3</td>
<td>740</td>
<td>50</td>
<td>9</td>
<td>N3 vs. N2</td>
<td>1.18</td>
<td>0.0006</td>
</tr>
</tbody>
</table>

HR, hazard ratio.

FIGURE 2. Survival by clinical T category, within clinical N categories.

with N3 contralateral mediastinal nodes differed from that of patients with N3 supraclavicular nodes, and it could not address differences in outcome for ipsilateral versus contralateral supraclavicular nodal involvement. In the IASLC staging system, both ipsilateral and contralateral supraclavicular nodes are included in LD. Therefore, more precise nodal categories should be recorded in future validation studies that will have prospectively collected data.

In the past, the traditional radiotherapy ports for chest irradiation for SCLC were large and sometimes included...
“prophylactic” treatment of areas such as the contralateral hilum and both supraclavicular fossae. In essence, therefore, treatment frequently paralleled the IASLC definition of limited disease. However, only moderate dose radiation could be delivered to such large volumes. The inability to deliver high doses to these large volumes may, in part, explain the high rates of failure at the primary site reported in most studies despite the administration of thoracic radiotherapy. Several recent trends make more precise nodal staging critical for SCLC. As is the case in NSCLC, reduction of the radiotherapy field size to cover only the known area of macroscopic disease is being recommended for SCLC. Also, the high local failure rate despite the addition of radiation to chemotherapy is leading to the investigation of higher radiation doses or

<table>
<thead>
<tr>
<th>Stage</th>
<th>N</th>
<th>1-yr Survival (%)</th>
<th>5-yr Survival (%)</th>
<th>Comparison</th>
<th>HR</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>211</td>
<td>77</td>
<td>38</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IB</td>
<td>325</td>
<td>67</td>
<td>21</td>
<td>IB vs. IA</td>
<td>1.48</td>
<td>0.0003</td>
</tr>
<tr>
<td>IIA</td>
<td>55</td>
<td>85</td>
<td>38</td>
<td>IIA vs. IB</td>
<td>0.62</td>
<td>0.0075</td>
</tr>
<tr>
<td>IIB</td>
<td>270</td>
<td>70</td>
<td>18</td>
<td>IIB vs. IIA</td>
<td>1.57</td>
<td>0.0118</td>
</tr>
<tr>
<td>IIIA</td>
<td>1170</td>
<td>59</td>
<td>13</td>
<td>IIIA vs. IIB</td>
<td>1.32</td>
<td>0.0003</td>
</tr>
<tr>
<td>IIIB</td>
<td>1399</td>
<td>50</td>
<td>9</td>
<td>IIIB vs. IIIA</td>
<td>1.21</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IV</td>
<td>4530</td>
<td>22</td>
<td>1</td>
<td>IV vs. IIIB</td>
<td>2.16</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

HR, hazard ratio.

more aggressive combined radio-chemotherapy regimens.\textsuperscript{30–32} To avoid toxicity from large volume fields, it will be essential to identify the most appropriate patients for such therapy, and more precise staging will be key to the ability to do this. It will also be very important to examine the patient populations in reports of clinical trials of altered fractionation and high-dose radiation (particularly single-arm phase I or II studies) because all patients with LD as defined by the IASLC may not be included in those studies, and this may have an effect on the survival outcomes. For example, in the landmark Turrisi trial, patients with pleural effusions, regardless of the cytology, and those with contralateral hilar or supraclavicular adenopathy were excluded.\textsuperscript{30} In this analysis, the survival of patients with IIIA and IIBB disease seems to be less than that

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure4}
\caption{Survival by (A) clinical sixth edition of TNM, including only those cases with sufficient information to derive IASLC proposed TNM stage; (B) IASLC proposed TNM stage; (C) survival by IASLC proposed TNM stage in the Surveillance, Epidemiology and End Results database.}
\end{figure}
reported in recent trials of high-dose radiation, hyperfractionated radiation, or concurrent chemotherapy and radiation therapy in LD SCLC. This may, in part, be because of less aggressive treatment practices in some parts of the globe where concurrent chemotherapy and radiation is seldom administered and where high-dose or hyperfractioned radiation is not considered standard. Alternatively, however, these survival rates may be a more accurate reflection of the true outcome of LD SCLC than those reported from clinical trials in which trial patients are a highly selected subgroup of LD overall.

If the proposals made by the IASLC for the forthcoming (seventh) edition of the TNM classification for lung cancer are accepted by the UICC and the AJCC, patients with pleural effusion will, in the future, be classified as having M1 (or extensive) disease. Our analysis shows that patients who have pleural effusion without extrathoracic metastases (M1a) have a survival that is intermediate between that of stage I–III without effusion and stage IV. A similar observation was reported by Perng et al. in a series of patients treated in Taiwan. Therefore, we recommend that pleural effusion should be a stratification parameter in clinical trials for both LD and ED SCLC. Having even a small proportion of patients with pleural effusion in LD trials could affect outcome significantly if they are not balanced between the arms, as could patients with only a pleural effusion in ED trials. Unfortunately, we did not have enough patients in our analysis to make a clear statement concerning cytology-positive or -negative effusions. Similarly, no information was available with respect to the presence of a pericardial effusion. This information must be collected prospectively in future studies.

It seems that TNM staging can identify subgroups of patients with distinct prognoses from within the broad definition of LD. However, the question still remains as to the value of applying the TNM system of staging to all patients with LD SCLC. Exact TNM stage is unlikely to alter treatment decisions for most patients with LD because combined modality therapy will be offered to patients with good performance status in most subsets of stage I, II, or III. The only potential exception to this might be the subgroup of patients with N3 supraclavicular nodal involvement, whether unilateral or bilateral. Whether to include supraclavicular nodes in the radiation treatments field remains an unresolved issue and is one that will require careful documentation for future prospective database analyses.

Our analysis suggests that, in the context of clinical trials in LD, accurate TNM staging may be critical and suggests that stratification based on TNM stage may be important. Survivals for clinical stages I and II are significantly different from those of stage III with N2 or N3 involvement. Therefore, the SCLC staging subcommittee of the IASLC Lung Cancer Staging Project recommends that TNM staging should be applied to SCLC and that stratification for stage should be incorporated into all trials in LD SCLC, particularly those addressing thoracic and prophylactic cranial radiation questions and those that include a surgical treatment arm. The small survival differences that are expected in these trials could be affected significantly by imbalances in the two patient subgroups of stage I/II versus III. For tumor registries, the clinical and, where possible, pathologic TNM designations should be recorded. It will always be possible to derive the LD and ED subsets from these data.

In summary, the proposals made by the IASLC for the forthcoming (seventh) edition of the TNM staging system seem to have relevance to SCLC. The SCLC subcommittee of the IASLC Lung Cancer Staging Committee therefore recommends that TNM staging be applied in SCLC and that stratification by TNM stage be incorporated into clinical trials in stage I-III SCLC. For prospective staging validation studies, more information must be collected to define the N category more clearly and to determine whether there is a difference in prognosis for patients with cytology-negative or -positive pleural effusions and for patients with pericardial effusions. In addition, in future studies, data concerning other prognostic variables, such as gender and performance status, and more detailed staging data should also be collected for multivariate analysis to isolate the effect of stage in this malignancy.

REFERENCES


APPENDIX 1

**IASLC International Staging Committee:**

P. Goldstraw (Chairperson), Royal Brompton Hospital, London, UK; H. Asamura, National Cancer Centre Hospital, Tokyo, Japan; D. Ball, Peter MacCallum Cancer Centre, East Melbourne, Australia; V. Bolejack, Cancer Research and Biostatistics, Seattle, Washington, USA; E. Brambilla, Laboratoire de Pathologie Cellulaire, Grenoble Cedex, France; P. A. Bunn, University of Colorado Health Sciences, Denver, Colorado; D. Carney, Mater Misericordiae Hospital, Dublin, Ireland; K. Chansky, Cancer Research and Biostatistics, Seattle, Washington, USA; T. Le Chevalier, Institute Gustave Roussy, Villejuif, France; J. Crowley, Cancer Research and Biostatistics, Seattle, Washington, USA; R. Ginsberg (deceased), Memorial Sloan-Kettering Cancer Center, New York, USA; D. Giroux, Cancer Research And Biostatistics, Seattle, Washington, USA; P. Groome, Queen’s Cancer Research Institute, Kingston, Ontario, Canada; H. H. Hansen (retired), National University Hospital, Copenhagen, Denmark; P. Van Houette, Institute Jules Bordet, Bruxelles, Belgium; J-G Im, Seoul National University Hospital, Seoul, South Korea; J. R. Jett, Mayo Clinic, Rochester, Minnesota, USA; H. Kato, (retired), Tokyo Medical University, Tokyo Japan; C. Kennedy, University of Sydney, Sydney, Australia; M. Krasnik, Gentofte Hospital, Copenhagen, Denmark; J. van Meerbeeck, University Hospital, Ghent, Belgium; T. Naruke (deceased), Saiseikai Central Hospital, Tokyo, Japan; E. F. Patz, Duke University Medical Center, Durham, North Carolina, USA; P. E. Postmus, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; R. Rami-Porta, Hospital Mutua de Terrassa, Terrassa, Spain; V. Rusch, Memorial Sloan-Kettering Cancer Center, New York, USA; JP. Sculier, Institute Jules Bordet, Bruxelles, Belgium; Z. Shaiikh, Royal Brompton Hospital, London, UK; F. A. Shepherd, University of Toronto, Toronto, Ontario, Canada; Y. Shimose (retired), National Cancer Centre, Tokyo, Japan; L. Sobin, Armed Forces Institute of Pathology, Washington, DC; W. Travis, Memorial Sloan-Kettering Cancer Center, New York; M. Tsuibo, Tokyo Medical University, Tokyo, Japan; R. Tsuchiya, National Cancer Centre, Tokyo, Japan; E. Vallieres, Swedish Cancer Institute, Seattle, Washington, USA; J. Vansteenkiste, Leuven Lung Cancer Group, Belgium; Yoh Watanabe, Kanazawa Medical University, Uchida, Japan; and H. Yokomise, Kagawa University, Kagawa, Japan.

**PARTICIPATING INSTITUTIONS:**

O. Visser, Amsterdam Cancer Registry, Amsterdam, The Netherlands; R. Tsuchiya and T. Naruke, Japanese Committee of Lung Cancer Registry; J. P. Van Meerbeeck, Flemish Lung Cancer Registry-VRGT, Brussels, Belgium; H. Bülzebruck, Thorax-klinik am Universitätsklinikum, Heidelberg, Germany; R. Allison and L. Tripcony, Queensland Radiation Institute, Herston, Australia; X. Wang, D. Watson and J. Herndon, Cancer and Leukemia Group B (CALGB), USA; R. J. Stevens, Medical Research Council Clinical Trials Unit, London, England; A. Depierre, E. Quoix and Q. Tran, Intergroupe Francophone de Cancerologie Thoracique (IFCT), France; J. R. Jett and S. Mandrekar, North Central Cancer Treatment Group (NCCTG), USA; J.H. Schiller and R. J. Gray, Eastern Cooperative Oncology Group (ECOG), USA; J.L. Duque-Medina and A. Lopez-Encuentra, Broncho-Pulmonary Oncology Team (BLOT), USA; R. J. Stevens, Medical Research Council Clinical Trials Unit, London, England; A. Depierre, E. Quoix and Q. Tran, Intergroupe Francophone de Cancerologie Thoracique (IFCT), France; J. R. Jett and S. Mandrekar, North Central Cancer Treatment Group (NCCTG), USA; J.H. Schiller and R. J. Gray, Eastern Cooperative Oncology Group (ECOG), USA; J.L. Duque-Medina and A. Lopez-Encuentra, Broncho-Pulmonary Oncology Team (BLOT), USA; T. E. Strand, Cancer Registry of Norway; S. Swann and H. Choy, Radiation Therapy Oncology Group (RTOG), USA; R. Damhuis, Rotterdam Cancer Registry, The Netherlands; P. E. Postmus, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; R. Rami-Porta, Hospital Mutua de Terrassa, Terrassa, Spain; V. Rusch, Memorial Sloan-Kettering Cancer Center, New York, USA; JP. Sculier, Institute Jules Bordet, Bruxelles, Belgium; Z. Shaiikh, Royal Brompton Hospital, London, UK; F. A. Shepherd, University of Toronto, Toronto, Ontario, Canada; Y. Shimose (retired), National Cancer Centre, Tokyo, Japan; L. Sobin, Armed Forces Institute of Pathology, Washington, DC; W. Travis, Memorial Sloan-Kettering Cancer Center, New York; M. Tsuibo, Tokyo Medical University, Tokyo, Japan; R. Tsuchiya, National Cancer Centre, Tokyo, Japan; E. Vallieres, Swedish Cancer Institute, Seattle, Washington, USA; J. Vansteenkiste, Leuven Lung Cancer Group, Belgium; Yoh Watanabe, Kanazawa Medical University, Uchida, Japan; and H. Yokomise, Kagawa University, Kagawa, Japan.
Netherlands; R. Komaki and P. K. Allen, MD Anderson Cancer Center- Radiation Therapy (MDACC-RT), Houston, Texas, USA; J. P. Sculier and M. Paesmans, European Lung Cancer Working Party (ELCWP); Y. L. Wu, Guangdong Provincial People’s Hospital, Peoples Republic of China; M. Pesek and H. Krosnarova, Faculty Hospital Plzen, Czech Republic; T. Le Chevalier and A. Dunant, International Adjuvant Lung Cancer Trial (IALT), France; B. McCaughan and C. Kennedy, University of Sydney, Sydney, Australia; F. Shepherd and M. Whitehead, National Cancer Institute of Canada (NCIC); J. Jassem and W. Ryzman, Medical University of Gdansk, Poland; G. V. Scagliotti and P. Borasio, Universita’ Degli Studi di Torino, S Luigi Hospital, Orbassano, Italy; K. M. Fong and L. Passmore, Prince Charles Hospital, Brisbane, Australia; V. W. Rusch and B. J. Park, Memorial Sloan-Kettering Cancer Center, USA; H. J. Baek, Korea Cancer Centre Hospital, Seoul, South Korea; R.P. Perng, Taiwan Lung Cancer Society, Taiwan; R. C. Yung, A. Gramatikova, John Hopkins University, USA; A. Vansteenkiste, Leuven Lung Cancer Group (LLCG), Belgium; C. Brambilla and M. Colonna, Grenoble University Hospital-Isere Cancer Registry, France; J. Hunt and A. Park, Western Hospital, Melbourne Australia; J. P. Sculier and T. Berghmans, Institute of Jules Bordet, Brussels, Belgium; A. K. Cangir, Ankara University School of Medicine, Ankara, Turkey; D. Subotic, Clinical Centre of Serbia, Belgrade, Serbia; R. Rosell and V. Aberola, Spanish Lung Cancer Group (SLCG), Spain; A. A. Vaporciyan and A. M. Correa, MD Anderson Cancer Center-Thoracic and Cardiovascular Surgery (MDACC-TCVS), Houston, Texas, USA; J. P. Pignon, T. Le Chevalier and R. Komaki, Institut Gustave Roussy (IGR), Paris, France; T. Orłowski, Institute of Lung Diseases, Warsaw, Poland; D. Ball and J. Matthews, Peter MacCallum Cancer Institute, East Melbourne, Australia; M. Tsao, Princess Margaret Hospital, Toronto, Ontario, Canada; S. Darwish, Policlinic of Perugia, Italy; H. I. Pass and T. Stevens, Karmanos Cancer Institute, Wayne State University, USA; G. Wright, St Vincent’s Hospital, Victoria, Australia; and C. Legrand and J. P. van Meerbeeck, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.